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Purpose: The goal of Electronic Medical Records and Genomics (eMERGE) Phase III Network
was to return actionable sequence variants to 25,084 consenting participants from 10 different
health care institutions across the United States. The purpose of this study was to evaluate
system-based issues relating to the return of results (RoR) disclosure process for clinical grade
research genomic tests to eMERGE3 participants.
Methods: RoR processes were developed and approved by each eMERGE institution’s internal
review board. Investigators at each eMERGE3 site were surveyed for RoR processes related to
the participant’s disclosure of pathogenic or likely pathogenic variants and engagement with
genetic counseling. Standard statistical analysis was performed.
Results: Of the 25,084 eMERGE participants, 1444 had a pathogenic or likely pathogenic variant
identiﬁed on the eMERGEseq panel of 67 genes and 14 single nucleotide variants. Of these, 1077
(74.6%) participants had results disclosed, with 562 (38.9%) participants provided with variant-speciﬁc
genetic counseling. Site-speciﬁc processes that either offered or required genetic counseling in their RoR
process had an effect on whether a participant ultimately engaged with genetic counseling (P = .0052).
Conclusion: The real-life experience of the multiarm eMERGE3 RoR study for returning
actionable genomic results to consented research participants showed the impact of consent,
method of disclosure, and genetic counseling on RoR.
© 2022 American College of Medical Genetics and Genomics.
Published by Elsevier Inc. All rights reserved.
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Introduction
Increased accessibility to genetic testing provides challenges
to medical professionals caring for the growing number of
individuals found to have a genetic predisposition to a
speciﬁc condition or disease. The Electronic Medical Records and Genomics (eMERGE) Network1 is one of several
National Institutes of Health–sponsored networks, which
include
Clinical
Sequencing
Evidence-Generating
Research,2 Clinical Genomic Resource,3 Implementing
Genomics in Practice,4 and All of Us5 that are evaluating the
use of DNA sequence results in clinical care.
At the time the study was conducted, the American
College of Genetics and Genomics (ACMG) had designated
59 genes as highly actionable owing to availability of
effective medical management guidelines for individuals
with detected disease-causing variants in one of these genes.
When an individual elects to have clinical genetic testing,
the ACMG recommends that laboratories interrogate and
return pathogenic (P) or likely pathogenic (LP) variants in
these actionable genes and report them as secondary ﬁndings to the individual.6 Although this guideline is based on
professional consensus, there is no empirical evidence to
direct best practices for returning secondary ﬁndings to
participants in clinical care or research. For those who
receive unanticipated results associated with clinical testing,
it has been within the context of clinical care with consent
obtained before sample submission. Individuals who undergo genomic sequencing through other avenues, such as
research studies or direct-to-consumer (DTC) testing, typically have no primary indication for testing. Thus, all
ﬁndings in these situations are unexpected because testing
was performed outside the clinical context with potentially
less access to genetic counseling and anticipatory guidance
for gene-speciﬁc management. Establishing best practices
and guidelines for the return of disease-causing variants,
identiﬁed through either screening studies or as secondary
ﬁndings, would support the utility of personalized genomic
medicine for a population.7
In addition, the need for best practices for the return of
ﬁndings is heightened by the expansion of genomic medicine in clinical care, particularly evident in cancer genetics.
Speciﬁc genetic variants can drive therapeutic options, such
as the use of PARP inhibitors for patients with a pathogenic
variant in BRCA1 or BRCA2.8 The Ofﬁce of Public Health
Genomics in the Centers for Disease Control and Prevention
is considering population screening for highly penetrant
genetic disorders and has nominated hereditary breast and
ovarian cancer, Lynch syndrome, and familial hyperlipidemia as Tier 1 conditions for initial implementation.9 If this
occurs, well-deﬁned processes will be required for consent,
testing, and return of genomic results. Moreover, the combination of the clinical utility associated with identifying
disease-causing genetic variants and a limited genetic
workforce will likely encourage the development of a
testing ﬁrst model before genetic counseling. This highlights
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the necessity for understanding the potential impact of such
a model to guide well-deﬁned processes for genomic testing
and return of results (RoR).10
In the eMERGE3 study, approximately 25,000 participants were enrolled from 10 different health care systems and
underwent sequencing of about 100 actionable genes,
including 58 genes from the ACMG incidental ﬁnding list.6
P/LP variants identiﬁed in these genes were returned
to consented participants. One of the speciﬁc aims of
eMERGE3 was the evaluation of the RoR process, including
consent, methods for RoR, disclosure of results to participants, informing of health care providers, and uploading of
results to the electronic health record (EHR). However, there
was no predetermined, prescribed process for RoR across the
clinical sites, permitting each site to develop their own RoR
process. Wiesner et al11 described the wide heterogeneity
between the eMERGE site-speciﬁc processes, including sitespeciﬁc source of participants (biorepositories, clinic, or
community), consent protocols, method of RoR disclosure to
participants, informing of health care providers, and participant engagement in genetic counseling. With the conclusion
of eMERGE3, we report on how a clinical site’s RoR process
had an effect on results disclosed to a participant and whether
genetic counseling was provided. Despite the variation between eMERGE3 sites for RoR, common themes were found
in the observed results, illustrating the real-life challenges of
returning unsolicited genomic results to participants. Our
experience of RoR across the eMERGE3 Network will inform
and guide future genomic research projects and implementation efforts.

Materials and Methods
eMERGE3 clinical sites
Brieﬂy, the 10 health care institutions that participated in
eMERGE3 were Cincinnati Children’s Hospital and Medical Center (CCHMC), Children’s Hospital of Philadelphia
(CHOP), Columbia University (CU), Geisinger (GE), Kaiser
Permanente of Washington (KPWA; formerly Group Health
Cooperative)/University of Washington (UW), Mayo Clinic
(MC), Meharry Medical College (MMC), Northwestern
University (NU), Partners HealthCare (PHC) (now Massachusetts General/Brigham), and Vanderbilt University
Medical Center (VUMC), with several sites having more
than 1 cohort (CCHMC, CU, and MC). The details of the
speciﬁc cohorts, population demographics, enhanced
recruitment based on phenotype or ethnicity, and planned
RoR process for eMERGE3 have been previously
described.11 Of the 10 clinical sites, 2 sites (CCHMC and
CHOP) exclusively enrolled pediatric participants, whereas
the other 8 clinical sites only enrolled adults. Depending on
the site, participants were recruited from biorepository
samples, prospectively from clinical sites, and through
community health care systems or a combination of these
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sources. Methods of disclosure include US mail, phone,
clinic appointment, EHR portal, or email. Genetic counseling was offered by all sites, but some sites speciﬁcally
required/embedded genetic counseling in their RoR protocols (Table 1). The RoR process for each site was
approved by each individual site’s institutional internal review board and human subjects committee.

eMERGE3 sequencing
The Clinical Laboratory Improvement Amendments/College of American Pathologists–certiﬁed sequencing laboratories for eMERGE3, the Partners HealthCare Laboratory
for Molecular Medicine and the Baylor College of Medicine
Human Genome Sequencing Center Clinical Laboratory,
used the eMERGEseq platform with 109 genes, including
58 actionable genes from the ACMG list,6 and 1555 single
nucleotide variants (SNVs) in additional genes. The
consensus panel returned by nearly all sites included 67
genes and 14 SNVs that were deemed actionable by the
eMERGE Network;1 additional genes returned were determined by the site’s protocol or existing biobank protocols
established before eMERGE3. Genes not returned by a
given clinical site were not included on participant reports
for that site. There was also variability in the types of results
disclosed. For example, 1 site disclosed heterozygous status
for common autosomal recessive conditions, 4 sites disclosed pharmacogenomic information, and 6 sites disclosed
null result information.12 Variants of uncertain signiﬁcance
were disclosed for colorectal cancer at the KPWA/UW site
in conjunction with enhanced recruitment at that site for
participants with colorectal cancer and colon polyps.
Sequencing laboratories began releasing results to clinical
sites in November 2017, and for the purposes of this report,

were considered complete as of April 2020 (see eMERGE
Clinical Annotation Working Group13 for details on distribution of returned ﬁndings). For the purpose of this study,
we only considered participants who received P/LP results
for the eMERGEseq consensus 67-gene panel and 14 clinically relevant SNVs.13
There were speciﬁc considerations for RoR at the pediatric clinical sites. CCHMC enrolled 2 cohorts, a biobank
cohort and a prospective adolescent cohort. Because the
biobank cohort represented all age ranges and was not
prospectively given a choice about the type of results to
return, CCHMC requested that only the genes for medically
actionable conditions during childhood be analyzed by the
sequencing laboratory, fewer than the 67 consensus gene
panel. All genes for medically actionable conditions,
including those for adult-onset conditions, were analyzed
for CCHMC’s prospective adolescent cohort, but returned
results were restricted to those that matched adolescent/
parent dyad choices.14,15 A genetic counselor returned P/LP
results to both the adolescent and parent by phone. Adolescents in the CCHMC prospective cohort were not given
the option to change which results they wanted to learn once
they turned 18. For the CCHMC and CHOP biobank participants, children/adolescent results were returned to parents. Although genes associated with adult-onset conditions
were analyzed for CHOPs biobank participants, P/LP variants for these conditions were withheld until the participant
turned 18, consented as an adult to the biobank, and then
recontacted for results disclosure.16

Data collection
Data used in this manuscript were obtained from a detailed
questionnaire that was developed by a subgroup of authors

Table 1 eMERGE3 sites, population type, source of recruitment, whether RoR was required at the time of enrollment, primary planned
method for RoR, and whether genetic counseling was embedded or offered in the RoR process
Group

Institution

Age Group

Group A

GE
NU
VUMC
CU

Adult
Adult
Adult
Adult

KPWA/UW
MC
MMC
PHC
CCHMC

Adult
Adult
Adult
Adult
Pediatric

CHOP

Pediatric

Group B

Source of Participants
Biorepository
Clinic, PGx biorepository
Clinic, PGx biorepository
Community clinic,
biorepository
Biorepository
Biorepository
Clinic
Biorepository
Biorepository, clinic,
community
Biorepository

RoR Required
for Enrollment

Primary Planned
Method for RoR

Genetic Counseling
with RoRa

Yes
Yes
Yes
No

Letter
Phone
Letter
Clinic, portal, letter, email

Offered
Offered
Offered
Embedded

No
No
No
No
No

Clinic
Clinic
Clinic
Clinic
Clinic, portal

Embedded
Embedded
Embedded
Embedded
Embedded

No

Clinic

Embedded

The 3 institutions with adult populations (GE, NU, and VUMC) and genetic counseling offered in the RoR are listed ﬁrst (Group A), followed by the 5 other
adult institutions (CU, KPWA/UW, MC, MMC, PHC) and the 2 pediatric institutions (CCHMC and CHOP) (group B).
CCHMC, Cincinnati Children’s Hospital and Medical Center; CHOP, Children’s Hospital of Philadelphia; CU, Columbia University; eMERGE3, Electronic Medical
Records and Genomics Phase III; GE, Geisinger; KPWA, Kaiser Permanente of Washington; MC, Mayo Clinic; MMC, Meharry Medical College; NU, Northwestern
University; PGx, pharmacogenomics; PHC, Partners HealthCare; RoR, return of results; UW, University of Washington; VUMC, Vanderbilt University Medical
Center.
a
CU, MC and CCHMC had multiple subpopulations.
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(K.A.L, G.L.W., and A.K.R.) and distributed during the
second year of RoR to investigators at each of the clinical
sites. The goal of the questionnaire was to gather detailed
information regarding the RoR process and the challenges
and barriers encountered. The questionnaire also assessed
sites’ use of genetic counseling in RoR, whether genetic
counseling was offered or speciﬁcally embedded in the
site-speciﬁc RoR process. The eMERGE3 Coordinating
Center at VUMC tracked and recorded RoR data for each
clinical site. Variables that were examined for impact on
RoR included differences between adult and pediatric
populations, how participants were consented into
eMERGE3, RoR disclosure process, and whether participants engaged in genetic counseling. For the purposes of
analysis, sites were grouped by consent process, whether
participant engagement was needed for results disclosure,
and whether genetic counseling was offered (group A) or
embedded/required (group B) in the RoR processes
(Table 1). Group A (GE, NU, and VUMC) required
participant consent to RoR at the time of enrollment, used
disclosure methods that did not require participant
engagement, and offered genetic counseling with RoR.
Group B (CCHMC, CHOP, CU, KPWA/UW, MC,
Meharry Medical College, and PHC) allowed participants
to decline RoR after samples were submitted for
sequencing, required participant engagement for RoR, and
embedded genetic counseling in their RoR process. Chisquare analysis was performed to evaluate the ability of
group A and group B to disclose genomic results to participants and to evaluate participant engagement in genetic
counseling between group A and group B.

Results
Of the 25,084 participants in eMERGE3, 1444 had at least 1
P/LP variant eligible for RoR; of these 1444 participants, 35
had P/LP variants in 2 different genes. The overall frequency of P/LP variants among eMERGE participants was
5.7%, ranging from 2.8% to 10.3% at an individual site
depending on initial sampling method and site-speciﬁc
criteria for RoR. P/LP variants were disclosed to 1077 of
the 1444 eMERGE3 participants (74.6%) (Table 2).
Comparing adult and pediatric populations, overall, 82.5%
of adults had results disclosure ranging from 24.7% to
97.5% across adult cohorts and clinical sites, whereas 24.2%
of pediatric participants had RoR ranging between 20.9%
and 83.3% across cohorts and clinical sites.
Clinical sites differ in whether a participant was
required to have results disclosed as part of the inclusion
criteria at the time of enrollment in eMERGE3 (group A)
or whether a participant could decline RoR after they were
included in a site’s eMERGE3 cohort (group B). Although
consented biorepository samples were used for both group
A and B, the requirement for RoR at the time of enrollment
ultimately affected the proportion of participants with
RoR. Of the 767 participants in group A, 92.3% of participants had P/LP results disclosed. This is compared with
the 677 participants across 7 clinical sites in group B,
where 54.5% of participants completed results disclosure.
When separating the adult and pediatric sites in group B,
the 5 eMERGE3 adult sites disclosed results to 66.9% of
participants, compared with 24.2% of the participants at
the 2 pediatric sites.

Table 2 eMERGE3 sites listed with total number of participants, number of participants with P/LP variants, and number of participants
with disclosed P/LP variants
Institution
CCHMC prospective adolescent
CCHMC biobank
CHOP
Columbia IMAgene
Columbia- prospective
Columbia -retrospective
Geisinger
KPWA/UW
Mayo - Rochester
Mayo - Arizona
Meharry
Northwestern
Partners Healthcare
VUMC
Total

Total Number of
Participants

Number of Participants
with P/LP Variants

160
2840
2990
341
1120
1135
2500
2500
2535
500
500
3000
2500
2454
25,084

6 (3.8%)
91 (3.2%)
101 (3.4%)
30 (8.8%)
65 (5.8%)
73 (6.4%)
263 (10.5%)
96 (3.8%)
121 (4.8%)
10 (2.0%)
19 (3.8%)
279 (9.3%)
65 (2.6%)
225(9.1%)
1444 (5.7%)

Number of Participants
with Returned P/LP
5
19
24
28
51
18
244
58
118
9
14
255
25
209
1077

(83.3%)
(20.9%)
(23.8%)
(93.3%)
(78.5%)
(24.7%)
(92.8%)
(60.4%)
(97.5%)
(90.0%)
(73.7%)
(88.5%)
(35.5%)
(92.9%)
(74.6%)

CCHMC, CU and MC have multiple listings representing different cohorts.
CCHMC, Cincinnati Children’s Hospital and Medical Center; CHOP, Children’s Hospital of Philadelphia; eMERGE3, Electronic Medical Records and Genomics
Phase III; KPWA, Kaiser Permanente of Washington; LP, likely pathogenic; MC, Mayo Clinic; P, pathogenic; UW, University of Washington; VUMC, Vanderbilt
University Medical Center.
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Site-speciﬁc processes for RoR included an in-person
appointment with a medical geneticist and/or genetic
counselor, phone call (typically with a genetic counselor or
other health care professional), use of a patient portal in the
EHR, and use of US postal mail. Some sites included
multiple contact methods within their RoR process. CU and
PHC allowed participants to choose their RoR disclosure
method. GE and VUMC (group A) used US postal mail as
the initial contact. However, GE’s initial mail outreach
informed the participant that information important to their
health was available and that the study team would contact
them with speciﬁc information,17 whereas VUMC’s letter
contained information about the speciﬁc gene involved and
the identiﬁed P/LP variant with instructions to discuss with
their primary care. Genetic counselors at NU used an unscheduled phone call to disclose results as the initial
outreach. Similar to GE, MC and KPWA/UW (group B)
used letters notifying participants that there was a clinically
relevant result but required participants to contact the site
and meet with a medical geneticist and/or genetic counselor
to complete result disclosure. When consented participants
could not be reached by the planned RoR process, some
sites used other methods, such as certiﬁed US postal mail,
for disclosure. GE, by using multiple methods to notify a
participant that a result was available, including mail, patient
portal, and telephone outreach, was able to ultimately
disclose 92.8% of results. By using US mail, VUMC disclosed results to 92.9% of their participants. Group A sites
were able to disclose results largely without participant
engagement to a similar percentage of their participants,
ranging from 88.5% to 92.9%. The group B sites, which
required a participant initiation to activate a portal or to
schedule an appointment with a health care provider, had a
broader variability in their ability to disclose results, ranging
from 20.9% to 97.5%, with an overall average of 74.6% of
participants with results disclosure. Of note, although letters
containing eMERGE3 results were sent by US postal mail, it
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is unknown whether these participants opened their mail and
were aware of their results. Ultimately, results for all
eMERGE3-consented participants were included in the
EHR. However, it was unknown how many eMERGE3
participants learned of their results from their EHR.
Of the 1444 participants with at least 1 P/LP variant, 367
(25.4%) did not have results disclosed (Figure 1). Of these,
116 were no longer eligible for RoR based on institutionspeciﬁc protocol(s) or because they were deceased. Across
all sites, 33 (2.3%) actively declined RoR. These were
participants who previously consented to RoR or had consented biorepository samples included in the eMERGE3
cohort but actively declined results when offered disclosure.
Another 134 (9.3%) were considered to have passively
withdrawn from eMERGE3 because they did not respond to
the site-speciﬁc RoR process after multiple attempts. A total
of 75 participants could not be located for RoR. At the time
of the data freeze for this analysis, 9 participants were still in
the RoR process.
A full genetic counseling session for eMERGE3 participants was considered to include a discussion of health
implications of the identiﬁed disease-associated variant,
management and surveillance recommendations, and family
risk information. As part of the site-speciﬁc protocol, genetic counselors may disclose results without providing
genetic counseling. Overall, 562 (38.9%) of the 1444
eMERGE3 participants engaged in genetic counseling as
part of site-speciﬁc protocols for RoR. Genetic counseling
could occur by phone or clinic visit (Figure 2) and was
offered at group A sites as part of RoR processes but was
embedded in the RoR process at group B sites. Of the 767
participants at group A sites with P/LP variants, 708 had
RoR, with 272 (38.4%) formally engaging in genetic
counseling. Of the 677 participants at group B sites with
P/LP variants, 369 participants had results disclosed, and
290 (42.8%) of those engaged in genetic counseling. There
is a signiﬁcant difference (P = .0052) between sites that did

Figure 1 Outcome of disclosure of P/LP variants to eMERGE3 participants. Diagram illustrating the number of enrolled participants
in eMERGE3, participants with return of results, and the breakdown of numbers and reasons why participants did not have return of results.
eMERGE3, Electronic Medical Records and Genomics Phase III; LP, likely pathogenic; P, pathogenic.
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Figure 2 Genetic counselling and the return process for P/LP results. Diagram illustrating RoR and genetic counselling for participants, broken down between 3 sites that did not have genetic counselling embedded in RoR (group A: Geisinger, Northwestern University,
Vanderbilt University Medical Center) vs the 7 sites that had genetic counselling embedded in their RoR process (group B: Cincinnati
Children’s Hospital and Medical Center, Children’s Hospital of Philadelphia, Columbia, Kaiser Permanente of Washington/University of
Washington, Mayo, Meharry, Partners HealthCare). eMERGE3, Electronic Medical Records and Genomics Phase III; LP, likely pathogenic;
P, pathogenic; RoR, return of results.

not require genetic counseling for RoR (group A; 38.4%)
and sites where it was embedded for RoR (group B; 42.8%).
This difference is more pronounced (P = .00001) when
comparing the overall RoR completion between these
groups (group A, 92.3% disclosed vs group B, 54.5% disclosed; P = .00001). This likely reﬂects the combined differences in the site processes of recruitment, consent, and
requirements for RoR disclosure.

Discussion
One of the great promises of genomic medicine is to provide
tailored management and surveillance to individuals with a
highly penetrant disease-causing genetic variant with the
hope of decreasing or ameliorating associated disease. With
actionable genomic variants increasingly identiﬁed by the
expansion of genetic testing in research, clinical care, and
DTC platforms, there is a growing need to identify best
practices for returning such results and ultimately, incorporating the information regarding disease-associated genetic variants into an individual’s health management.
As a ﬁrst step toward developing general guidance, we
report on the impact of heterogeneous RoR processes across

10 clinical sites in the eMERGE3 Network and identify
factors impacting RoR. The purpose of comparing rates of
RoR between clinical sites was not to measure which process was more or less successful in disclosing results to
participants but to illuminate what barriers inﬂuence the
disclosure of actionable genomic results to research participants, including both children and adults, and whether
participants choose to engage in genetic counseling as part
of RoR. This analysis highlights issues regarding consent
for RoR at the time of enrollment in eMERGE3, methods of
disclosing results to participants and whether that method of
disclosure required participant engagement, and ﬁnally,
participant engagement in genetic counseling.
eMERGE3 sites that included only participants who consented to RoR at the time of enrollment (group A) had the
highest number of participants with results disclosed. Group
B had a lower RoR in sites that used samples from previously
consented biorepository participants but not speciﬁcally for
eMERGE3. Attempts to reconsent these individuals after
sequencing resulted in many participants, either actively or
passively, withdrawing from the study; therefore, sites
allowing participants to opt out of disclosure at different
points in the RoR process ultimately disclosed fewer results.
Pediatric sites faced the unique challenge of children
transitioning to age 18 years between sample collection
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and site receipt of the Clinical Laboratory Improvement
Amendments report, necessitating reconsent as an adult
before results could be returned. In addition, CHOPs internal review board required withholding of results for adultonset conditions to biobank participants until they turned
18 and signed consent for RoR.16 Of the 116 participants
across eMERGE3 that were no longer eligible to receive
their results, 65 (56%) were from the 2 pediatric sites.
The method of RoR, and whether result disclosure required
participant engagement, affected RoR. Active participant
engagement in care is required to schedule an in-person or
phone appointment with a healthcare professional or to activate
a portal for results disclosure. We suspect that RoR processes
that required participant engagement in genetic counseling
allowed more opportunity for participants to passively withdraw from or actively decline results disclosure.
Although it is essential to examine the underlying reasons for participants’ acceptance or refusal of an eMERGE3
actionable result, the demographics of these participants and
reasons why the 33 participants actively declined or 134
participants passively declined RoR were not possible to
measure across the eMERGE3 Network for this project.
However, a site-speciﬁc analysis by Henrikson et al18 of
1131 eMERGE3 participants at KPWA/UW who did not
respond to requests for disclosure (ie, passive refusal) of
their eMERGE3 results suggests that passive refusal may
represent a true desire not to receive genomic information.
On follow-up contact with these 1131 participants, 71%
actively refused RoR, citing reasons of insurance concerns,
privacy, and not wanting the results.
RoR processes did not necessarily imply engagement with
genetic counseling because site-speciﬁc processes may or
may not have had genetic counseling embedded in their RoR
process. In total, across the eMERGE3 Network, 38.9% of the
1444 participants with P/LP variants had results disclosed and
received genetic counseling. The number of participants who
actually received genetic counseling is likely higher because
some participants had prior knowledge and previous genetic
counseling for their disease-associated variant. We are anecdotally aware that genetic counseling was provided to some
eMERGE3 participants by physicians or healthcare providers
that were not medical geneticists or genetic counselors.
However, this information was not tracked as an outcome for
eMERGE3 participants. As the knowledge of the impact of
genetics and genomics disseminates across all ﬁelds of health
care, it will be necessary to determine whether individuals
who do not formally engage with genetic services receive and
understand the necessary information for themselves and
family members at risk. Studies have shown that individuals
who receive information about a pathogenic variant in the
context of genetic counseling are more likely to receive
tailored management recommendations and are more likely to
have cascade testing of family members.18
The strength of the eMERGE3 Network is the heterogeneity of RoR processes that reﬂect the multiple differences in health care organization structure and resources in
the United States. Despite this complexity, certain patterns
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become evident when considering factors that impact result
disclosure and can guide best practices for genomic medicine. This study highlights that when participants in
genomic research are recruited with speciﬁc enrollment
criteria to receive results and use passive methods for result
disclosure, without required genetic counseling, results can
be returned to nearly all participants. But is this the best
practice? Additional analysis of factors having an effect on
the willingness of participants to engage with their genomic
test results represents important information for directing
both clinical practice and future research studies. Given the
low proportion of participants who had genetic counseling
observed across eMERGE3, other methods of providing
genetic care need to be evaluated. The historic paternalism
around genetic diagnosis and the perceived need for genetic
counseling as the sole way to disclose results and provide
management and information to family members may be
creating barriers for identifying individuals with genetic
risk.19 Research studies are needed to determine whether
more individuals at risk for a highly penetrant genetic
condition are best identiﬁed by population screening vs
attempting cascade screening through an index patient.
The results reported here have some limitations and must
be understood in the context of the eMERGE3 Network.
First, the percentage of P/LP variants reported here (5.8%) is
notably higher than the frequency of secondary ﬁndings
reported previously (3.02%)13 owing to the heterogeneous
nature of the participant populations across the 10 eMERGE
sites. Sites varied by enrolling for phenotypic indications or
enrichment for P/LP ﬁndings.17 Second, this project focused
on the systems-based impact and effectiveness of the RoR
processes. The impact of processes downstream, such as use
of health care services and cascade testing, are beyond the
scope of this evaluation. Finally, each individual site RoR
processes differed in the required point of contact and
level of engagement in RoR, causing some of the observed
variability; however, this heterogeneity illuminates the factors important to the clinical utility of genomic screening in
the real world that can guide future research investigations
and clinical care implementation.
Genetic and genomic testing and research will continue
to expand through clinical care, DTC, and research projects
such as All of Us. The list of genes considered actionable by
the ACMG was 59 genes at the time of eMERGE3 and has
recently been expanded to 73 genes.20 There may be routine
adult population screening for hereditary breast and ovarian
cancer, Lynch syndrome, and familial hyperlipidemia
because the Centers for Disease Control and Prevention
considers these Tier 1 conditions as having a high impact on
public health. Finally, the SARS-CoV-2 pandemic has had a
dramatic impact on transitioning health care to virtual care,
which will likely continue and increase access to further
impact genetic care. To conclude, the eMERGE3 RoR
project provides results of an observational, pragmatic study
of genomic medicine implementation across different health
care systems and populations. Barriers experienced by sites
and adaptations to the eMERGE3 RoR processes illuminate
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issues of consent, contact, engagement, and participation in
genetic counseling to be considered before broader implementation of DNA sequence results into health care.

Data Availability
All data sets summarized in this article can be requested on
the Electronic Medical Records and Genomics website
https://emerge-network.org.
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